secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016735
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive
--------------------------------------------------------------------------------

- Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.
- Total revenue of $19.0M, up from $1.7M year-over-year, driven by $17.9M licensing revenue.
- Cash, equivalents and marketable securities of $248.1M as of Sep 30, 2022; sufficient to fund operations through end of 2025.
- Phase 2a enrollment completed for zunsemetinib in hidradenitis suppurativa (95 patients); topline data expected mid-first half 2023.
- ATI-2138 Phase 1 SAD trial completed; generally well-tolerated, dose-dependent ITK/JAK3 inhibition; ulcerative colitis selected as first target; new IND submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/0001558370-22-016735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/acrs-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer